Device: Desktop
Opening
a new frontier
in pharmacology
Opening
a new frontier
a new frontier
in pharmacology
Opening
a new frontier
in pharmacology
A pipeline of pharmacological inhibitors
with a unique mechanism of action
Signaling Specific inhibitors
of the CB1 (CB1-SSi)
of the CB1 (CB1-SSi)
Targeting disease states of the brain while preserving normal behavior
AEF0117 for cannabis related disorders
AEF0217 for the treatment of cognitive deficits
Aelis Farma’s Mission
”
To combine the scientific breakthrough of CB1 with innovative drug development to provide new effective and safe treatments for brain diseases with unmet medical needs.
“
Pier Vincenzo Piazza, CEO
Latest News
Latest News
Aelis Farma announces the Last Patient, Last Visit in its clinical phase 2b trial with AEF0117 for the treatment of cannabis use disorder
April 2024
+
Aelis Farma Strengthens its Leadership Team with the Appointment of Arsène Guekam as Chief Corporate Development Officer
January 2024
+